STAT Plus: CRISPR’s pioneers reflect on the first gene-editing treatment
Jennifer Doudna, Emmanuelle Charpentier, Feng Zhang, and George Church reflect on the approval of Casgevy, the first CRISPR-based drug.
Read The StoryCRISPR is a gene editing technology that allows scientists to make precise changes to DNA. Here you can learn about the companies developing CRISPR-based treatments, and the tremendous potential in its use.
For the latest CRISPR advances, check out STAT’s searchable CRISPR Trackr.
Jennifer Doudna, Emmanuelle Charpentier, Feng Zhang, and George Church reflect on the approval of Casgevy, the first CRISPR-based drug.
Read The Storyadvertisement